Quote Originally Posted by drillerpie View Post
I've got no idea either, but if I was faced with a choice between squeezing an extra bit of effectiveness out of an already effective enough vaccine but potentially catapulting everyone back to square one by creating a vaccine resistant version of the virus, or rolling the vaccines out more slowly, a quick cost/benefit analysis would push me fairly quickly towards the latter.
This reminds me of another interview I saw last week on Sky News where an(other) expert said that in the event that a vaccine-resistant strain does emerge, tweaking the existing vaccines to address that problem is a much simpler, easier, quicker process than designing a vaccine from scratch. It sounds logical to me, but again it's a matter for those who know.